Posted on July 28, 2026August 28, 2026 by — Leave a comment

Pinealon 10mg Dosage Protocol

Dosage Protocol

Pinealon 10mg Dosage Protocol

A concise laboratory preparation and measurement reference for a 10mg Pinealon vial reconstituted with 2mL.

Evidence boundary: No validated human injectable Pinealon schedule has been established. The conversions below describe solution concentration and U-100 volume measurements, not a recommended administration amount.

Vial amount10mg

Preparation volume2mL

Final concentration5mg/mL

Preparation

Use a validated aseptic laboratory workflow and inspect the sealed vial before preparation.
Add 2mL of the selected sterile diluent slowly against the vial wall.
Allow the material to dissolve without vigorous shaking.
Label the prepared vial with the concentration, preparation date, and storage conditions.

U-100 Measurement Reference

At 5mg/mL, each U-100 unit represents 0.01mL and contains 0.05mg (50mcg) of material.

U-100 marking	Volume	Material measured
1 unit	0.01mL	0.05mg / 50mcg
5 units	0.05mL	0.25mg / 250mcg
10 units	0.10mL	0.50mg / 500mcg
20 units	0.20mL	1.00mg

Calculation

Concentration: 10mg / 2mL = 5mg/mL. Material measured: syringe volume in mL x 5mg/mL.

Storage and Evidence Limits

Keep the prepared vial refrigerated unless a validated laboratory protocol specifies otherwise. Protect it from light, minimize temperature cycling, and avoid repeated freeze-thaw cycles.

Published Pinealon work spans cellular and animal models using model-specific concentrations and routes. Those experiments do not establish a transferable human injection schedule, clinical efficacy, or long-term safety.

Research-use disclaimer: This page is a laboratory calculation reference, not medical advice. Products discussed are for research use only and are not intended for human consumption.

Posted on July 28, 2026August 28, 2026 by — Leave a comment

Pinealon 20mg Dosage Protocol

Dosage Protocol

Pinealon 20mg Dosage Protocol

A concise laboratory preparation and measurement reference for a 20mg Pinealon vial reconstituted with 2mL.

Vial amount20mg

Preparation volume2mL

Final concentration10mg/mL

Preparation

Use a validated aseptic laboratory workflow and inspect the sealed vial before preparation.
Add 2mL of the selected sterile diluent slowly against the vial wall.
Allow the material to dissolve without vigorous shaking.
Label the prepared vial with the concentration, preparation date, and storage conditions.

U-100 Measurement Reference

At 10mg/mL, each U-100 unit represents 0.01mL and contains 0.10mg (100mcg) of material.

U-100 marking	Volume	Material measured
1 unit	0.01mL	0.10mg / 100mcg
5 units	0.05mL	0.50mg / 500mcg
10 units	0.10mL	1.00mg
20 units	0.20mL	2.00mg

Calculation

Concentration: 20mg / 2mL = 10mg/mL. Material measured: syringe volume in mL x 10mg/mL.

Storage and Evidence Limits

Keep the prepared vial refrigerated unless a validated laboratory protocol specifies otherwise. Protect it from light, minimize temperature cycling, and avoid repeated freeze-thaw cycles.

Research-use disclaimer: This page is a laboratory calculation reference, not medical advice. Products discussed are for research use only and are not intended for human consumption.

Posted on July 27, 2026August 28, 2026 by — Leave a comment

Tirzepatide 20mg Dosage Protocol

Preparation & Measurement Guide

Tirzepatide 20mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Tirzepatide 20mg vial.

Research use only
Educational comparator summary. This research material is not an approved drug product.

Vial Size
Tirzepatide 20mg

Preparation
2mL bacteriostatic water

Concentration
10mg/mL after preparation

Documented Convention
2.5-15mg once weekly

1. Preparation and Measurement

Tirzepatide 20mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 10mg/mL. On a U-100 syringe, each unit contains 100mcg.

20mg / 2mL = 10mg/mL

1 U-100 unit = 0.01mL = 100mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in approved comparator products. Frequency: once weekly.

Period	Documented amount	Measurement
Weeks 1-4	2.5mg once weekly	0.25mL / 25 units
Weeks 5-8	5mg once weekly	0.5mL / 50 units
Weeks 9-12	7.5mg once weekly	0.75mL / 75 units
Weeks 13-16	10mg once weekly	1mL / 100 units
Weeks 17-20	12.5mg once weekly	1.25mL / 125 units*
Weeks 21+	15mg once weekly	1.5mL / 150 units*

Vial estimate: One 20mg vial contains approximately 8 administrations at the first listed amount or 1 at the final listed amount.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
An asterisk marks measurements above 1mL, which exceed the capacity of a standard 1mL U-100 syringe.
Record the amount, date, and preparation used.

3. Supplies Needed

Tirzepatide 20mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Tirzepatide is the active molecule in approved prescription products with indication-specific titration, contraindications, warnings, and device instructions.

The table documents the approved weight-management escalation pattern as a comparator. A laboratory vial is not an approved drug product and is not interchangeable with a regulated injector.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

Tirzepatide 40mg Dosage Protocol

Preparation & Measurement Guide

Tirzepatide 40mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Tirzepatide 40mg vial.

Research use only
Educational comparator summary. This research material is not an approved drug product.

Vial Size
Tirzepatide 40mg

Preparation
2mL bacteriostatic water

Concentration
20mg/mL after preparation

Documented Convention
2.5-15mg once weekly

1. Preparation and Measurement

Tirzepatide 40mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 20mg/mL. On a U-100 syringe, each unit contains 200mcg.

40mg / 2mL = 20mg/mL

1 U-100 unit = 0.01mL = 200mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in approved comparator products. Frequency: once weekly.

Period	Documented amount	Measurement
Weeks 1-4	2.5mg once weekly	0.125mL / 12.5 units
Weeks 5-8	5mg once weekly	0.25mL / 25 units
Weeks 9-12	7.5mg once weekly	0.375mL / 37.5 units
Weeks 13-16	10mg once weekly	0.5mL / 50 units
Weeks 17-20	12.5mg once weekly	0.625mL / 62.5 units
Weeks 21+	15mg once weekly	0.75mL / 75 units

Vial estimate: One 40mg vial contains approximately 16 administrations at the first listed amount or 2 at the final listed amount.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
Record the amount, date, and preparation used.

3. Supplies Needed

Tirzepatide 40mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Tirzepatide is the active molecule in approved prescription products with indication-specific titration, contraindications, warnings, and device instructions.

The table documents the approved weight-management escalation pattern as a comparator. A laboratory vial is not an approved drug product and is not interchangeable with a regulated injector.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

Tirzepatide 5mg Dosage Protocol

Preparation & Measurement Guide

Tirzepatide 5mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Tirzepatide 5mg vial.

Research use only
Educational comparator summary. This research material is not an approved drug product.

Vial Size
Tirzepatide 5mg

Preparation
1mL bacteriostatic water

Concentration
5mg/mL after preparation

Documented Convention
2.5-15mg once weekly

1. Preparation and Measurement

Tirzepatide 5mg With 1mL of Diluent

Add 1mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

5mg / 1mL = 5mg/mL

1 U-100 unit = 0.01mL = 50mcg

Preparation

Draw 1mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in approved comparator products. Frequency: once weekly.

Period	Documented amount	Measurement
Weeks 1-4	2.5mg once weekly	0.5mL / 50 units
Weeks 5-8	5mg once weekly	1mL / 100 units
Weeks 9-12	7.5mg once weekly	1.5mL / 150 units*
Weeks 13-16	10mg once weekly	2mL / 200 units*
Weeks 17-20	12.5mg once weekly	2.5mL / 250 units*
Weeks 21+	15mg once weekly	3mL / 300 units*

Vial estimate: One 5mg vial contains approximately 2 administrations at the first listed amount; later rows exceed one vial’s total content.

Practical Notes

The table applies only to this vial prepared with exactly 1mL.
An asterisk marks measurements above 1mL, which exceed the capacity of a standard 1mL U-100 syringe.
Some later entries also exceed the total material in one vial and are shown only to preserve the documented schedule comparison.
Record the amount, date, and preparation used.

3. Supplies Needed

Tirzepatide 5mg vial.
1mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Tirzepatide is the active molecule in approved prescription products with indication-specific titration, contraindications, warnings, and device instructions.

The table documents the approved weight-management escalation pattern as a comparator. A laboratory vial is not an approved drug product and is not interchangeable with a regulated injector.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

TB-500 5mg Dosage Protocol

Preparation & Measurement Guide

TB-500 5mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a TB-500 5mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
TB-500 5mg

Preparation
1mL bacteriostatic water

Concentration
5mg/mL after preparation

Documented Convention
500mcg-1mg once daily

1. Preparation and Measurement

TB-500 5mg With 1mL of Diluent

Add 1mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

5mg / 1mL = 5mg/mL

1 U-100 unit = 0.01mL = 50mcg

Preparation

Draw 1mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period	Documented amount	Measurement
Weeks 1-2	500mcg once daily	0.1mL / 10 units
Weeks 3-4	750mcg once daily	0.15mL / 15 units
Weeks 5-8	1mg once daily	0.2mL / 20 units

Vial estimate: One 5mg vial contains approximately 10 administrations at the first listed amount or 5 at the final listed amount.

Practical Notes

The table applies only to this vial prepared with exactly 1mL.
Record the amount, date, and preparation used.

3. Supplies Needed

TB-500 5mg vial.
1mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

TB-500 is associated with thymosin beta-4 research involving cell migration, wound models, and tissue repair. Commercial TB-500 material should not be assumed identical to full-length thymosin beta-4 used in published studies.

TB-500 is not an approved therapeutic drug. No clinically validated dosing schedule has been established.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

Tesamorelin 10mg Dosage Protocol

Preparation & Measurement Guide

Tesamorelin 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Tesamorelin 10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
Tesamorelin 10mg

Preparation
2mL bacteriostatic water

Concentration
5mg/mL after preparation

Documented Convention
1.4mg once daily

1. Preparation and Measurement

Tesamorelin 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL

1 U-100 unit = 0.01mL = 50mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in the approved comparator formulation. Frequency: once daily.

Period	Documented amount	Measurement
Documented approved-drug comparator	1.4mg once daily	0.28mL / 28 units

Vial estimate: One 10mg vial contains approximately 7 documented-size administrations at 1.4mg.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
Record the amount, date, and preparation used.

3. Supplies Needed

Tesamorelin 10mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Tesamorelin is the active molecule in an approved prescription product for a specific indication. The current approved formulation uses a formulation-specific 1.4mg daily amount and preparation method.

The table uses that amount only as a comparator. A laboratory vial is not the approved product, and its preparation instructions must not be assumed equivalent to the prescription formulation.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

Tesamorelin 15mg Dosage Protocol

Preparation & Measurement Guide

Tesamorelin 15mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Tesamorelin 15mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
Tesamorelin 15mg

Preparation
1.5mL bacteriostatic water

Concentration
10mg/mL after preparation

Documented Convention
1.4mg once daily

1. Preparation and Measurement

Tesamorelin 15mg With 1.5mL of Diluent

Add 1.5mL of bacteriostatic water to the vial. The resulting concentration is 10mg/mL. On a U-100 syringe, each unit contains 100mcg.

15mg / 1.5mL = 10mg/mL

1 U-100 unit = 0.01mL = 100mcg

Preparation

Draw 1.5mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in the approved comparator formulation. Frequency: once daily.

Period	Documented amount	Measurement
Documented approved-drug comparator	1.4mg once daily	0.14mL / 14 units

Vial estimate: One 15mg vial contains approximately 10 documented-size administrations at 1.4mg.

Practical Notes

The table applies only to this vial prepared with exactly 1.5mL.
Record the amount, date, and preparation used.

3. Supplies Needed

Tesamorelin 15mg vial.
1.5mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

The table uses that amount only as a comparator. A laboratory vial is not the approved product, and its preparation instructions must not be assumed equivalent to the prescription formulation.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

Tesamorelin 5mg Dosage Protocol

Preparation & Measurement Guide

Tesamorelin 5mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Tesamorelin 5mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
Tesamorelin 5mg

Preparation
1mL bacteriostatic water

Concentration
5mg/mL after preparation

Documented Convention
1.4mg once daily

1. Preparation and Measurement

Tesamorelin 5mg With 1mL of Diluent

Add 1mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

5mg / 1mL = 5mg/mL

1 U-100 unit = 0.01mL = 50mcg

Preparation

Draw 1mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in the approved comparator formulation. Frequency: once daily.

Period	Documented amount	Measurement
Documented approved-drug comparator	1.4mg once daily	0.28mL / 28 units

Vial estimate: One 5mg vial contains approximately 3 documented-size administrations at 1.4mg.

Practical Notes

The table applies only to this vial prepared with exactly 1mL.
Record the amount, date, and preparation used.

3. Supplies Needed

Tesamorelin 5mg vial.
1mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

The table uses that amount only as a comparator. A laboratory vial is not the approved product, and its preparation instructions must not be assumed equivalent to the prescription formulation.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

Thymosin Alpha-1 10mg Dosage Protocol

Preparation & Measurement Guide

Thymosin Alpha-1 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Thymosin Alpha-1 10mg vial.

Research use only
Educational comparator summary. This research material is not an approved drug product.

Vial Size
Thymosin Alpha-1 10mg

Preparation
2mL bacteriostatic water

Concentration
5mg/mL after preparation

Documented Convention
1.6mg twice weekly

1. Preparation and Measurement

Thymosin Alpha-1 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL

1 U-100 unit = 0.01mL = 50mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in published clinical research. Frequency: twice weekly.

Period	Documented amount	Measurement
Weeks 1-12	1.6mg twice weekly	0.32mL / 32 units

Vial estimate: One 10mg vial contains approximately 6 documented-size administrations at 1.6mg.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
Record the amount, date, and preparation used.

3. Supplies Needed

Thymosin Alpha-1 10mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Thymosin alpha-1 has been examined in clinical studies involving immune regulation, infection, and inflammatory responses. Results vary by condition, study design, and background treatment.

The 1.6mg convention appears in published clinical research, but this research material is not an approved drug product and should not be treated as equivalent to a regulated formulation.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

Tirzepatide 10mg Dosage Protocol

Preparation & Measurement Guide

Tirzepatide 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Tirzepatide 10mg vial.

Research use only
Educational comparator summary. This research material is not an approved drug product.

Vial Size
Tirzepatide 10mg

Preparation
2mL bacteriostatic water

Concentration
5mg/mL after preparation

Documented Convention
2.5-15mg once weekly

1. Preparation and Measurement

Tirzepatide 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL

1 U-100 unit = 0.01mL = 50mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in approved comparator products. Frequency: once weekly.

Period	Documented amount	Measurement
Weeks 1-4	2.5mg once weekly	0.5mL / 50 units
Weeks 5-8	5mg once weekly	1mL / 100 units
Weeks 9-12	7.5mg once weekly	1.5mL / 150 units*
Weeks 13-16	10mg once weekly	2mL / 200 units*
Weeks 17-20	12.5mg once weekly	2.5mL / 250 units*
Weeks 21+	15mg once weekly	3mL / 300 units*

Vial estimate: One 10mg vial contains approximately 4 administrations at the first listed amount; later rows exceed one vial’s total content.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
An asterisk marks measurements above 1mL, which exceed the capacity of a standard 1mL U-100 syringe.
Some later entries also exceed the total material in one vial and are shown only to preserve the documented schedule comparison.
Record the amount, date, and preparation used.

3. Supplies Needed

Tirzepatide 10mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Tirzepatide is the active molecule in approved prescription products with indication-specific titration, contraindications, warnings, and device instructions.

The table documents the approved weight-management escalation pattern as a comparator. A laboratory vial is not an approved drug product and is not interchangeable with a regulated injector.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

SS-31 50mg Dosage Protocol

Preparation & Measurement Guide

SS-31 50mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a SS-31 50mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
SS-31 50mg

Preparation
2mL bacteriostatic water

Concentration
25mg/mL after preparation

Documented Convention
5-15mg once daily

1. Preparation and Measurement

SS-31 50mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 25mg/mL. On a U-100 syringe, each unit contains 250mcg.

50mg / 2mL = 25mg/mL

1 U-100 unit = 0.01mL = 250mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period	Documented amount	Measurement
Weeks 1-2	5mg once daily	0.2mL / 20 units
Weeks 3-4	10mg once daily	0.4mL / 40 units
Weeks 5-8	15mg once daily	0.6mL / 60 units

Vial estimate: One 50mg vial contains approximately 10 administrations at the first listed amount or 3 at the final listed amount.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
Record the amount, date, and preparation used.

3. Supplies Needed

SS-31 50mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

SS-31, also studied as elamipretide, targets mitochondrial membranes and has been evaluated in preclinical models and human trials. Clinical results have been mixed, and trial formulations cannot be assumed equivalent to research material.

SS-31 is not approved for general therapeutic use. The table records a circulated convention and is not a clinical recommendation.